Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk
Authors: Charles B. Eaton MD
Journal: Annals of Internal Medicine (2016)

ACP Journal Club19 July 2016Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV riskCharles B. Eaton MD, MSCharles B. Eaton MD, MSAlpert Medical School of Brown University, Providence, Rhode Island, USA (C.B.E.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-165-2-008 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationYusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374:2032-43. https://pubmed.ncbi.nlm.nih.gov/27039945Clinical Impact RatingsGIM/FP/GP: Cardiology: References1 Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. [PMID: 9613910] Google Scholar2 Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207. [PMID: 18997196] Google Scholar3 Sever PS, Dahlöf B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58. [PMID: 12686036] Google Scholar4 Nakamura H, Arakawa K, Itakura H, et al; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155-63. [PMID: 17011942] Google Scholar5 Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90. [PMID: 22607822] Google Scholar6 Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-42. [PMID: 20167359] Google Scholar Author, Article, and Disclosure InformationAffiliations: Alpert Medical School of Brown University, Providence, Rhode Island, USA (C.B.E.)This article was published at Annals.org on 5 July 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk Charles B. Eaton MD Combination candesartan–HCTZ did not reduce major CV events in patients at intermediate CV risk Charles B. Eaton MD Combination candesartan–HCTZ did not reduce major CV events in patients at intermediate CV risk Charles B. Eaton MD Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk Charles B. Eaton MD Metrics 19 July 2016Volume 165, Issue 2Page: JC8KeywordsAdverse eventsBlood pressureCholesterolHeartLow density lipoproteinMedical risk factorsMusclesMyocardial infarctionRevascularizationStatins ePublished: 19 July 2016 Issue Published: 19 July 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...